Biennial mammography optimal screening interval for average risk women
the ONA take:
A comprehensive analysis of digital mammography tests has indicated that biennial (once every two years) screening is preferable for women of age 50 through 74 that have an average risk of developing breast cancer.
This screening frequency should offer a good balance between prudent detection and the risk of false-positive results.
The study findings indicated that biennial screening maintains an average of 81.2% of annual screening benefits with fewer false-positives; whereas annual screening, although it could avert 3 more cancer deaths, would yield approximately 1988 additional false-positive test results.
This study was a collaboration between six modeling research groups that belong to CISNET, the NCI-sponsored Cancer Intervention and Surveillance Modeling Network, coupled with investigators based at the Breast Cancer Surveillance Consortium (BCSC).
The paper's lead author was Jeanne S. Mandelblatt, MD, MPH, of Georgetown Lombardi Comprehensive Cancer Center (CISNET).
The modeling incorporated national data on breast cancer risk, treatment effects, and incidence of breast cancer; and reviewed one- and two-year screening intervals on individuals with varying starting ages. The research also considered digital screening and breast density factors.
Other modeling findings revealed that biennial screening during the age span of 50-74 would achieve a roughly 25% mortality reduction. Starting the biennial screening at age 40 averts an average of one additional cancer death but also generates an average of 576 additional false-positive tests.
The paper's lead author cautioned that these model findings should still not override a screening frequency determination based on individual factors, based on acceptance of false-positive results, over treatment, etc. She stated that screening frequency must be balanced against the risk of chemotherapy and/or radiation treatment that may not needed.
Biennial (once every two years) screening is preferable for women of age 50 through 74 that have an average risk of developing breast cancer.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|